Medicare estimates that the new Alzheimer’s treatment, Leqembi, could cost the program $3.5 billion in 2025, surpassing projections by Wall Street and the drug's manufacturer. Despite being the first drug to slow Alzheimer's, its sales have been slow, with major hospital systems taking months to adopt it and some insurers rejecting coverage. A document obtained by STAT reveals the significant financial impact on Medicare, raising questions about the allocation of resources for the drug.
That Medicare spending estimate for Leqembi? Some people are skeptical ... #pinksheet #Pharma: Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs https://t.co/HogNujsnWG
How a new kind of drug could change the future of Alzheimer’s https://t.co/dS70f3iGJk
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs https://t.co/VMvDLhKByO #PinkSheet
Alzheimer’s drug’s impact limited in U.S. https://t.co/O7vuDOyGen
Medicare expects a big spike in spending on the Alzheimer's drug Leqembi -- $3.5 billion by 2025. Read a new edition of Health Care Inc. https://t.co/yPiNFGgTzU
"What are we, as taxpayers, willing to spend on this drug with limited resources?” Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025. https://t.co/AXnhGcKgZa
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. https://t.co/hJknxe0Uvq
It’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start? https://t.co/uf7vq1dRzr
It’s the First Drug Shown to Slow Alzheimer’s. Why Is Is It Off to a Slow Start? https://t.co/MZXAYrjmqM
A Miami biotech developing a drug to treat Alzheimer's disease is cutting back on some research and development. Here's why. https://t.co/ESDVcKZJ64
The first drug shown to slow Alzheimer's disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. https://t.co/ng9FLGu1Mo
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start? https://t.co/Zyzifr9VWo https://t.co/5Eiax9ham8
New STAT exclusive: The Alzheimer’s treatment Leqembi could cost the entire Medicare program $3.5 billion in 2025, according to a document obtained by @bobjherman and @rachelcohrs. https://t.co/Fy6SwGhpQz
Medicare expects to spend $3.5 bln on a proven ineffective drug but will not cover anti-obesity meds with far superior data for positive health outcomes. Should we start calling obesity type 2 Alzheimer’s for better drug coverage? https://t.co/NST90LYBLb
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project. https://t.co/tABirskpYT
Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the program billions of dollars by next year — well beyond what Wall Street or even the drug’s manufacturer has projected — according to a document obtained by STAT. https://t.co/GEdAMvJ8XI
Medicare expects to spend $3.5 billion on the Alzheimer's treatment Leqembi in 2025 — well beyond what Wall Street or even the drug's manufacturer has projected. Read more from @rachelcohrs and me: https://t.co/ms8E2ekU8p